Geller Advisors LLC Alkermes Plc. Transaction History

Geller Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$26.4 - $32.56 $219,542 - $270,768	-8,316 Reduced 47.01%	9,375 $253,000
Q4 2023 Feb 14, 2024	BUY	$23.37 - $28.68 $23 - $28	1 Added 0.01%	17,691 $490,000
Q2 2023 Aug 09, 2023	BUY	$28.34 - $33.63 $226,436 - $268,703	7,990 Added 82.37%	17,690 $553,000
Q1 2023 May 12, 2023	BUY	$25.31 - $29.02 $245,507 - $281,494	9,700 New	9,700 $273,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Geller Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Geller Advisors LLC with notifications on news.